ArticleScientific reports2021
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The factors associated with mortality and progressive disease of nontuberculous mycobacterial lung disease: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Epidemiologic trends and mortality in nontuberculous mycobacterial lung disease: a nationwide cohort study in Taiwan (2011-2020).Journal of global health · 2026Article
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Early treatment interruption and nutritional status as predictors of mortality in Mycobacterium avium complex pulmonary disease.PloS one · 2026Article
- Molecular epidemiological surveillance for non-tuberculous mycobacterial pulmonary disease: a single-center prospective cohort study.Microbiology spectrum · 2025Article
- Primary cutaneous Mycobacteria avium complex infection in a systemic lupus erythematosus patient: A case report and review.Medicine · 2025Review
- Variability of macrolide-resistant profile inAntimicrobial agents and chemotherapy · 2024Article
- Article
- Review
- The diagnostic impact of fractional exhaled nitric oxide for asthmatic cough in nontuberculous mycobacterial pulmonary disease.BMC pulmonary medicine · 2024Article
- A Systematic Review of Factors Associated with Mortality among Patients withPathogens (Basel, Switzerland) · 2023Review
- Treatment outcomes and relapse in patients withMicrobiology spectrum · 2023Article
- MGIT-seq for the Identification of Nontuberculous Mycobacteria and Drug Resistance: a Prospective Study.Journal of clinical microbiology · 2023Article
- Management ofEuropean respiratory review : an official journal of the European Respiratory Society · 2022Review
- Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.Antimicrobial agents and chemotherapy · 2022Article
- Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity.Scientific reports · 2022Article
- Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model.Antibiotics (Basel, Switzerland) · 2021Review
- A Low Body Mass Index Is Associated with Unsuccessful Treatment in Patients withJournal of clinical medicine · 2021Article
- New/Different Look at the Presence ofMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment of Mycobacterium avium complex pulmonary disease (MAC-PD). However, poor adherence to the standardized regimens recommended by current guidelines have been reported. We undertook a single-centred retrospective cohort study to evaluate the long-term outcomes in 295 patients with MAC-PD following first line treatment with standard (RFP, EB, clarithromycin [CAM]) or alternative (EB and CAM with or without fluoroquinolones (FQs) or RFP, CAM, and FQs) regimens. In this cohort, 80.7% were treated with standard regimens and 19.3% were treated with alternative regimens. After heterogeneity was statistically corrected using propensity scores, outcomes were superior in patients treated with standard regimens. Furthermore, alternative regimens were significantly and independently associated with sputum non-conversion, treatment failure and emergence of CAM resistance. Multivariate cox regression analysis revealed that older age, male, old tuberculosis, diabetes mellitus, higher C-reactive protein, and cavity were positively associated with mortality, while higher body mass index and M. avium infection were negatively associated with mortality. These data suggest that, although different combination regimens are not associated with mortality, first line administration of a standard RFP + EB + macrolide regimen offers the best chance of preventing disease progression in MAC-PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.